Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Lymphoblastic lymphoma.

D A Thomas¹, H M Kantarjian

¹Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. debthomas@mdanderson.org

Hematology/Oncology Clinics of North America

|March 20, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Moving toward individualized target-based therapies in acute myeloid leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020

Same author

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

The pharmacogenomics journal·2017

Same author

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

Blood cancer journal·2017

Same author

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Leukemia·2017

Same author

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Leukemia·2017

Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026

Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026

See all related articles

Recent advances in lymphoblastic lymphoma (LL) show improved outcomes with intensive chemotherapy. Newer treatment strategies, including autologous intensification and bone marrow transplant, are enhancing patient prognosis and survival.

Area of Science:

Hematology
Oncology
Pathology

Background:

Lymphoblastic lymphoma (LL) is a distinct clinicopathologic entity.
Understanding LL's natural history and molecular biology is crucial for treatment.
Prognosis and outcomes have historically varied with different chemotherapy regimens.

Purpose of the Study:

To review recent advances in lymphoblastic lymphoma.
To detail the natural history, molecular biology, prognosis, and outcomes of LL.
To discuss the impact of various chemotherapy regimens and novel therapeutic modalities.

Main Methods:

Literature review of recent advances in LL.
Analysis of natural history, molecular biology, and prognostic factors.
Evaluation of outcomes with current and emerging treatment strategies.

Related Experiment Videos

Main Results:

Intensive chemotherapy regimens have led to improved outcomes in LL.
Novel therapeutic modalities like autologous intensification and allogeneic bone marrow transplant show promise.
Radiotherapy continues to play a role in LL management.

Conclusions:

Significant progress has been made in treating lymphoblastic lymphoma.
Intensive chemotherapy and advanced treatment modalities are improving patient prognosis.
Further research into LL pathogenesis and treatment optimization is warranted.